Newer Oral Levodopa Formulations in Parkinson’s Disease

This section discusses IPX203, a newer extended-release formulation of carbidopa/levodopa designed to provide more continuous dopaminergic stimulation for patients with Parkinson’s disease. The formulation combines an immediate-release component with a delayed-release portion that binds in the proximal small intestine and gradually releases levodopa over four to six hours. In the RISE-PD trial, patients who switched from optimized immediate-release carbidopa/levodopa to IPX203 experienced increased “on” time, reduced “off” time, and fewer troublesome dyskinesias. The study also demonstrated that patients required fewer daily doses—approximately three per day with IPX203 compared with about six per day with the immediate-release formulation. These findings suggest that IPX203 represents an advanced oral levodopa therapy that may help manage motor fluctuations while simplifying dosing and improving symptom control.